Alexander Dimitrios Colevas MD

Oncology•Palo Alto, CA

Head & Neck Cancer, Hematologic Oncology

Professor, Medicine - Oncology, Stanford University Medical Center

Join to View Full Profile

300 Pasteur DrPalo Alto, CA 94304
Phone+1 650-723-4000

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1993 - 1996
Johns Hopkins UniversityResidency, Internal Medicine, 1989 - 1992
Johns Hopkins University School of MedicineClass of 1989

Certifications & Licensure

CA State Medical License 2007 - 2026
MD State Medical License 1991 - 2008
MA State Medical License 1993 - 2001
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC) Start of enrollment: 2008 Dec 10
Completed
Phase 2
Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin Start of enrollment: 2013 Mar 01
Terminated
Phase 2
Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma Start of enrollment: 2017 Jul 17
Completed
Phase 2
Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Start of enrollment: 2011 Oct 01
Completed
Phase 2
Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies Start of enrollment: 2022 Jan 25
RECRUITING
PHASE2
Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer Start of enrollment: 2019 Feb 11
COMPLETED
PHASE1, PHASE2
Roles: Contact, Principal Investigator
Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) Start of enrollment: 2019 Apr 04
Terminated
Phase 1, Phase 2
Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN) Start of enrollment: 2017 May 01
Completed
Phase 1
Combination Chemotherapy in Treating Patients With Stage IIB, Stage III, or Stage IV Cancer of the Nasopharynx Start of enrollment: 1999 Aug 01
Unknown status
Phase 2
Join now to see all

Publications & Presentations

PubMed

2 citations
Automated patient selection and care coaches to increase advance care planning for patients with cancer.
Michael F Gensheimer, Winifred Teuteberg, Manali I Patel, Divya Gupta, Mahjabin Noroozi
Journal of the National Cancer Institute. 2025-02-01
4 citations
Immunotherapy for keratinocyte cancers. Part I: Immune-related epidemiology, risk factors, pathogenesis, and immunotherapy management of keratinocyte cancers.
Romy A Neuner, Jinwoo Lee, Kerri E Rieger, Caroline Park, Alexander D Colevas
Journal of the American Academy of Dermatology. 2023-06-01
11 citations
Generating in silico CODEX from a small set of immunofluorescence markers.
Eric Wu, Alexandro E Trevino, Zhenqin Wu, Kyle Swanson, Honesty J Kim
PNAS Nexus. 2023-06-01

Journal Articles

Identification and Validation of Novel Microenvironment-Based Immune Molecular Subgroups of Head and Neck Squamous Cell Carcinoma: Implications for Immunotherapy
J Ma, D N Hayes, A Dimitrios Colevas, N Lee, Annals of Oncology